Services of MTRC

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients to better understand the potential scope of our support. From the week of 29th of July, we are planning to work on 21 projects. Review the full list of planned activities in this post.

MTRC developed an analytical White Paper with a summary of key market access elements of EU5 countries, including stakeholders, payment mechanisms, innovative payment schemes, funding, and the role of HTA for in-vitro diagnostic tests.

In a new White Paper, MTRC identified evidence requirements for the creation of CCAM codes for diagnostic (non-IVD) procedures performed by physicians based on an analysis of four recent HAS reports with positive and negative recommendations. The analysis was performed in February 2024.

Market access is a rapidly changing field and the landscape varies for different types of medical technologies. To provide an additional, easy-to-access source of high-level information about key themes in the market access landscape and challenges for individual types of medical technologies, MTRC launched a dedicated Knowledge Zone on the website. Currently, the Knowledge Zone includes information about procedure coding, payment mechanisms, policy considerations, HTA, and future challenges for market access for 12 types of medical technologies. In the coming weeks, the Zone will expand 40 key technology groups

In a new White Paper, MTRC identified evidence requirement pitfalls that act as a barrier to listing in the LPPR based on analyzing five recent HAS reports with negative recommendations from different medical disciplines. The analysis was performed in January 2024.

MTRC released several short (2-4 minutes) educational videos on its YouTube channel: “Three common market access barriers for medical technologies”, “Reimbursement models and incentives for healthcare providers”, “How to spot a well-functioning DRG system?” and “Market access challenges for different types of medical technologies”. Videos can be of interest to an audience of both market access professionals and those new to the field of reimbursement, funding, HTA and market access for medical technologies in Europe.

In a new White Paper, MTRC identified evidence requirements for national add-on reimbursement via the LPPR List process based on analysis of five recent HAS reports with positive recommendations. Cases included technologies with different levels of added clinical value (II, III, IV, and V). A review of five cases is followed by recommendations in relation to evidence generation for medical technologies in France, and factors influencing the decision-making of HAS. The analysis was performed in February 2024.

MTRC is re-starting the release of educational videos on its YouTube channel. Videos will cover a wide range of topics, including reimbursement, funding, health technology assessment, and clinical and economic evidence requirements for medical technologies in European countries.

MTRC maintains a page with free, brief summaries of the market access landscape for medical technologies and in-vitro diagnostic tests in European countries, the Knowledge Zone. The intention of the Knowledge Zone is to become an easily accessible reference material to our clients about payment systems for medical technologies in Europe. The current version of the Knowledge Zone includes information about 30 countries: Austria, Belgium, Bulgaria, Croatia, the Czech Republic, Denmark, England, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxemburg, the Netherlands, Norway, Poland, Portugal, Romania, Scotland, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and Wales. For each country, information is provided about key market access challenges, payment mechanisms, funding and HTA barriers, and specifics of reimbursement of in-vitro diagnostic (IVD) tests.

Health technology assessment plays an important role in market access for medical technologies in England. NICE's early value assessment (EVA) program in medical technology, launched in 2022, assesses mostly digital technologies at an early stage in evidence generation. The program recommends the most promising technologies for use in the NHS while further evidence is being generated. NICE focuses on clinical effectiveness, safety, cost, and cost-effectiveness of the technologies. In this White Paper, MTRC performed a review of five recent EVA assessments by NICE to present the evidence requirements for digital and diagnostic medical technologies in this particular HTA program. A review of five cases is followed by recommendations in relation to evidence generation for medical technologies, market access in England, and factors influencing the decision-making of NICE.

Medical technologies face several market access challenges in Europe, including reimbursement, funding (post-reimbursement approval by payers), and health technology assessment. To overcome some of these challenges, Med Tech companies need to develop clinical and economic evidence to support the value claims about medical technologies. MTRC helps medical technology companies reduce uncertainty about evidence requirements of key European reimbursement, funding, and HTA authorities and develop a clear plan to address key gaps with clinical and economic evidence. A White Paper "Evidence Gap Analysis for Medical Technologies in Europe – a Practical Example" presents the methodological approach or MTRC and a practical example of evidence gap analysis.

MTRC announces the start of the new service – evidence gap analysis for medical technologies in Europe. The service helps to establish the sufficiency of existing evidence to obtain reimbursement and endorsement by HTA organizations in Europe and offers recommendations for the generation of missing evidence. MTRC offers a fact-based, unbiased approach to determining clinical and economic evidence requirements, based on the benchmarking to the prevision reimbursement decisions of reimbursement authorities and HTA organizations. Recommendations are also based on an in-depth understanding of the reimbursement pathways in individual markets. Learn more on the dedicated page for this service.